FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:238-248 July 21, 2005 Number 3 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined.

Methods We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined.

Results After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33).

Conclusions Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.

Source Information

From the Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany (C.W., V.K.); the Clinical Institute of Medical and Chemical Laboratory Diagnostics, University General Hospital, Graz, Austria (W.M.); the Department of Medical Biometrics and Statistics, University Hospital of Freiburg, Freiburg, Germany (M.O.); Schwabing General Hospital, Munich, Germany (J.F.E.M.); Clinical Research Department, Pfizer, Karlsruhe, Germany (G.R.); and the Department of Medicine, University of Heidelberg, Heidelberg, Germany (E.R.).

Address reprint requests to Dr. Wanner at the Department of Medicine, Division of Nephrology, University Hospital, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany, or at wanner_c{at}medizin.uni-wuerzburg.de.

Full Text of this Article

Related Letters:

Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Dialysis
Langer A., Robinson J. G., Jaber B. L., Madias N. E., Wanner C., Krane V., Ritz E.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1858-1860, Oct 27, 2005. Correspondence

This article has been cited by other articles:

• Ganguli, A., Kassimatis, T. I., Konstantinopoulos, P. A., de Oliveira, J. M. F., Fellstrom, B., Jardine, A., Holdaas, H., the AURORA Executive Steering Committee, (2009). Rosuvastatin in Patients Undergoing Hemodialysis. NEJM 361: 93-95 [Full Text]  
• de Bie, M. K., van Dam, B., Gaasbeek, A., van Buren, M., van Erven, L., Bax, J. J., Schalij, M. J., Rabelink, T. J., Jukema, J. W. (2009). The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur Heart J 30: 1559-1564 [Abstract] [Full Text]  
• Cleland, J. G.F., Coletta, A. P., Clark, A. L., Cullington, D. (2009). Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 11: 622-630 [Abstract] [Full Text]  
• Anderson, S., Halter, J. B., Hazzard, W. R., Himmelfarb, J., Horne, F. M., Kaysen, G. A., Kusek, J. W., Nayfield, S. G., Schmader, K., Tian, Y., Ashworth, J. R., Clayton, C. P., Parker, R. P., Tarver, E. D., Woolard, N. F., High, K. P., for the workshop participants, (2009). Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults. J. Am. Soc. Nephrol. 20: 1199-1209 [Abstract] [Full Text]  
• Drechsler, C., Krane, V., Grootendorst, D. C, Ritz, E., Winkler, K., Marz, W., Dekker, F., Wanner, C., for the German Diabetes and Dialysis Study Investi, (2009). The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant 0: gfp260v1-gfp260 [Abstract] [Full Text]  
• Floege, J. (2009). Reply. Nephrol Dial Transplant 0: gfp246v1-gfp246 [Full Text]  
• Piraino, B., Minev, E., Bernardini, J., Bender, F. H. (2009). DOES EXPERIENCE WITH PD MATTER?. pdi 29: 256-261 [Full Text]  
• Jassal, S. V., Lok, C. E. (2009). THE HONEYPOT: STICKY OR SWEET?. pdi 29: 267-269 [Full Text]  
• Ishii, H., Kumada, Y., Toriyama, T., Aoyama, T., Takahashi, H., Amano, T., Yasuda, Y., Yuzawa, Y., Maruyama, S., Matsuo, S., Matsubara, T., Murohara, T. (2009). Aortic valvular calcification predicts restenosis after implantation of drug-eluting stents in patients on chronic haemodialysis. Nephrol Dial Transplant 24: 1562-1567 [Abstract] [Full Text]  
• Lee, P.-S., Sampath, K., Karumanchi, S. A., Tamez, H., Bhan, I., Isakova, T., Gutierrez, O. M., Wolf, M., Chang, Y., Stossel, T. P., Thadhani, R. (2009). Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. J. Am. Soc. Nephrol. 20: 1140-1148 [Abstract] [Full Text]  
• Strippoli, G. F.M., Craig, J. C. (2009). Sunset for Statins after AURORA?. NEJM 360: 1455-1457 [Full Text]  
• Fellstrom, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Gronhagen-Riska, C., De Lima, J. J., Lins, R., Mayer, G., McMahon, A. W., Parving, H.-H., Remuzzi, G., Samuelsson, O., Sonkodi, S., Sci., D., Suleymanlar, G., Tsakiris, D., Tesar, V., Todorov, V., Wiecek, A., Wuthrich, R. P., Gottlow, M., Johnsson, E., Zannad, F., the AURORA Study Group, (2009). Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. NEJM 360: 1395-1407 [Abstract] [Full Text]  
• Laufs, U, Custodis, F, Bohm, M (2009). Who does not need a statin: too late in end-stage renal disease or heart failure?. Postgrad. Med. J. 85: 187-189 [Abstract] [Full Text]  
• Rigatto, C., Levin, A., House, A. A., Barrett, B., Carlisle, E., Fine, A. (2009). Atheroma Progression in Chronic Kidney Disease. CJASN 4: 291-298 [Abstract] [Full Text]  
• Krane, V., Heinrich, F., Meesmann, M., Olschewski, M., Lilienthal, J., Angermann, C., Stork, S., Bauersachs, J., Wanner, C., Frantz, S., for the German Diabetes and Dialysis Study Investi, (2009). Electrocardiography and Outcome in Patients with Diabetes Mellitus on Maintenance Hemodialysis. CJASN 4: 394-400 [Abstract] [Full Text]  
• Herzog, C. A. (2009). Kidney disease in cardiology. Nephrol Dial Transplant 24: 34-37 [Full Text]  
• Radbill, B., Murphy, B., LeRoith, D. (2008). Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clin Proc. 83: 1373-1381 [Abstract] [Full Text]  
• Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., Perri, D. (2008). Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments A Network Meta-Analysis Involving More Than 65,000 Patients.. J Am Coll Cardiol 52: 1769-1781 [Abstract] [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Harper, C. F., Jacobson, T. A. (2008). Reply. J Am Coll Cardiol 52: 1680-1680 [Full Text]  
• Wright, J., Vardhan, A. (2008). Review: The problem of diabetic nephropathy and practical prevention of its progression. British Journal of Diabetes & Vascular Disease 8: 272-277 [Abstract]  
• Seiler, S., Schlitt, A., Jiang, X.-C., Ulrich, C., Blankenberg, S., Lackner, K. J., Girndt, M., Werdan, K., Buerke, M., Fliser, D., Heine, G. H. (2008). Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. Nephrol Dial Transplant 23: 3599-3604 [Abstract] [Full Text]  
• Tepel, M., Hopfenmueller, W., Scholze, A., Maier, A., Zidek, W. (2008). Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 23: 3605-3612 [Abstract] [Full Text]  
• Wiesbauer, F., Heinze, G., Mitterbauer, C., Harnoncourt, F., Horl, W. H., Oberbauer, R. (2008). Statin Use Is Associated with Prolonged Survival of Renal Transplant Recipients. J. Am. Soc. Nephrol. 19: 2211-2218 [Abstract] [Full Text]  
• Ritz, E., Wanner, C. (2008). Statin Use Prolongs Patient Survival after Renal Transplantation. J. Am. Soc. Nephrol. 19: 2037-2040 [Full Text]  
• Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. (2008). Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis. J Am Coll Cardiol 52: 914-920 [Abstract] [Full Text]  
• Yang, X., So, W. Y., Ma, R., Ko, G., Kong, A., Lam, C., Ho, C. S., Cockram, C., Chow, C.-C., Tong, P., Chan, J. (2008). Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes--the Hong Kong Diabetes Registry. Nephrol Dial Transplant 23: 2834-2840 [Abstract] [Full Text]  
• Svensson, M., Schmidt, E. B., Jorgensen, K. A., Christensen, J. H. (2008). The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study. Nephrol Dial Transplant 23: 2918-2924 [Abstract] [Full Text]  
• Van Biesen, W., Verbeke, F., Vanholder, R. (2008). An infallible recipe? A story of cinnamon, souffle and meta-analysis. Nephrol Dial Transplant 23: 2729-2732 [Full Text]  
• Winkler, K., Wanner, C., Drechsler, C., Lilienthal, J., Marz, W., Krane, V., for the German Diabetes and Dialysis Study Investi, (2008). Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 29: 2092-2099 [Abstract] [Full Text]  
• Laufs, U, Custodis, F, Bohm, M (2008). Who does not need a statin: too late in end-stage renal disease or heart failure?. Heart 94: 1138-1140 [Abstract] [Full Text]  
• Herzog, C. A., Strief, J. W., Collins, A. J., Gilbertson, D. T. (2008). Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?. Nephrol Dial Transplant 23: 2629-2633 [Abstract] [Full Text]  
• Schlieper, G., Hristov, M., Brandenburg, V., Kruger, T., Westenfeld, R., Mahnken, A. H., Yagmur, E., Boecker, G., Heussen, N., Gladziwa, U., Ketteler, M., Weber, C., Floege, J. (2008). Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. Nephrol Dial Transplant 23: 2611-2618 [Abstract] [Full Text]  
• Johnston, N., Dargie, H., Jardine, A. (2008). Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease. Heart 94: 1080-1088 [Full Text]  
• Li, P. K.-T., Kwan, B. C.-H., Szeto, C. C., Ko, G. T.-C. (2008). Metabolic syndrome in peritoneal dialysis patients. NDT Plus 1: 206-214 [Abstract] [Full Text]  
• Shepherd, J., Kastelein, J. J. P., Bittner, V. A., Carmena, R., Deedwania, P. C., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A. L., Wenger, N. K., Treating to New Targets Steering Committee and Inv, (2008). Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease. Mayo Clin Proc. 83: 870-879 [Abstract] [Full Text]  
• Harper, C. R., Jacobson, T. A. (2008). Managing dyslipidemia in chronic kidney disease.. J Am Coll Cardiol 51: 2375-2384 [Abstract] [Full Text]  
• How, P. P., Mason, D. L., Lau, A. H. (2008). Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder. Journal of Pharmacy Practice 21: 196-213 [Abstract]  
• Ritz, E., Wanner, C. (2008). Lipid Abnormalities and Cardiovascular Risk in Renal Disease. J. Am. Soc. Nephrol. 19: 1065-1070 [Abstract] [Full Text]  
• Tonelli, M. (2008). Randomized Trials in Hemodialysis Patients: Time to Step Up to the Plate. JAMA 299: 2205-2207 [Full Text]  
• Mitterbauer, C., Heinze, G., Kainz, A., Kramar, R., Horl, W. H., Oberbauer, R. (2008). ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 23: 1742-1746 [Abstract] [Full Text]  
• Ritz, E., Wanner, C. (2008). The Challenge of Sudden Death in Dialysis Patients. CJASN 3: 920-929 [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the TNT (Treating to New Targets) Investigator, (2008). Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study. J Am Coll Cardiol 51: 1448-1454 [Abstract] [Full Text]  
• Aull-Watschinger, S., Konstantin, H., Demetriou, D., Schillinger, M., Habicht, A., Horl, W. H., Watschinger, B. (2008). Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant 23: 1429-1435 [Abstract] [Full Text]  
• Strippoli, G. F M, Navaneethan, S. D, Johnson, D. W, Perkovic, V., Pellegrini, F., Nicolucci, A., Craig, J. C (2008). Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336: 645-651 [Abstract] [Full Text]  
• Stenvinkel, P., Carrero, J. J., Axelsson, J., Lindholm, B., Heimburger, O., Massy, Z. (2008). Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?. CJASN 3: 505-521 [Abstract] [Full Text]  
• RIFKIN, D., SARNAK, M. (2008). Q: Should all patients with chronic kidney disease take a statin?. Cleveland Clinic Journal of Medicine 75: 118-120 [Full Text]  
• Richards, N., Harris, K., Whitfield, M., O'Donoghue, D., Lewis, R., Mansell, M., Thomas, S., Townend, J., Eames, M., Marcelli, D. (2008). Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 23: 549-555 [Abstract] [Full Text]  
• American College of Cardiology/American Heart Asso, , 2007 Writing Group to Review New Evidence and Upda, , King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O. (2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. J Am Coll Cardiol 51: 172-209 [Full Text]  
• King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, , Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W. (2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117: 261-295 [Full Text]  
• Garg, A. X., Greene, T., Levin, N. W. (2008). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrol Dial Transplant 23: 52-55 [Full Text]  
• Novak, J. E., Szczech, L. A. (2008). Feast and Famine: Epidemiology and Clinical Trials in Chronic Kidney Disease. J. Am. Soc. Nephrol. 19: 2-4 [Full Text]  
• Cleland, J. G.F., Coletta, A. P., Abdellah, A. T., Cullington, D., Clark, A. L., Rigby, A. S. (2008). Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. Eur J Heart Fail 10: 102-108 [Abstract] [Full Text]  
• Joy, M. S, Dornbrook-Lavender, K. A, Chin, H., Hogan, S. L, Denu-Ciocca, C. (2008). Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients. The Annals of Pharmacotherapy 42: 9-15 [Abstract] [Full Text]  
• Kessler, M., Zannad, F., Lehert, P., Grunfeld, J. P., Thuilliez, C., Leizorovicz, A., Lechat, P., for the FOSIDIAL Investigators, (2007). Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrol Dial Transplant 22: 3573-3579 [Abstract] [Full Text]  
• Henyan, N. N, Riche, D. M, East, H. E, Gann, P. N (2007). Impact of Statins on Risk of Stroke: A Meta-Analysis. The Annals of Pharmacotherapy 41: 1937-1945 [Abstract] [Full Text]  
• Khawar, O., Kalantar-Zadeh, K., Lo, W. K., Johnson, D., Mehrotra, R. (2007). Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?. CJASN 2: 1317-1328 [Abstract] [Full Text]  
• Khella, S., Bleicher, M. B. (2007). Stroke and Its Prevention in Chronic Kidney Disease. CJASN 2: 1343-1351 [Abstract] [Full Text]  
• Agarwal, R. (2007). Effects of Statins on Renal Function. Mayo Clin Proc. 82: 1381-1390 [Abstract] [Full Text]  
• Romayne Kurukulasuriya, L., Athappan, G., Saab, G., Whaley Connell, A., Sowers, J. R. (2007). Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Ther Adv Cardiovasc Dis 1: 49-59 [Abstract]  
• Macdougall, I. C., Eckardt, K.-U., Locatelli, F. (2007). Latest US KDOQI Anaemia Guidelines update what are the implications for Europe?. Nephrol Dial Transplant 22: 2738-2742 [Full Text]  
• Foley, R. N., Collins, A. J. (2007). End-Stage Renal Disease in the United States: An Update from the United States Renal Data System. J. Am. Soc. Nephrol. 18: 2644-2648 [Abstract] [Full Text]  
• Culleton, B. F., Walsh, M., Klarenbach, S. W., Mortis, G., Scott-Douglas, N., Quinn, R. R., Tonelli, M., Donnelly, S., Friedrich, M. G., Kumar, A., Mahallati, H., Hemmelgarn, B. R., Manns, B. J. (2007). Effect of Frequent Nocturnal Hemodialysis vs Conventional Hemodialysis on Left Ventricular Mass and Quality of Life: A Randomized Controlled Trial. JAMA 298: 1291-1299 [Abstract] [Full Text]  
• Jamison, R. L., Hartigan, P., Kaufman, J. S., Goldfarb, D. S., Warren, S. R., Guarino, P. D., Gaziano, J. M., For the Veterans Affairs Site Investigators, (2007). Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial. JAMA 298: 1163-1170 [Abstract] [Full Text]  
• Glynn, L. G., Reddan, D., Newell, J., Hinde, J., Buckley, B., Murphy, A. W. (2007). Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 22: 2586-2594 [Abstract] [Full Text]  
• Kalantar-Zadeh, K. (2007). Inflammatory Marker Mania in Chronic Kidney Disease: Pentraxins at the Crossroad of Universal Soldiers of Inflammation. CJASN 2: 872-875 [Full Text]  
• Chertow, G. M., Pupim, L. B., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., Goodman, W. G., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Albizem, M., Olson, K., Klassen, P., Parfrey, P. (2007). Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview. CJASN 2: 898-905 [Abstract] [Full Text]  
• Bleyer, A. J. (2007). Use of Antimicrobial Catheter Lock Solutions to Prevent Catheter-Related Bacteremia. CJASN 2: 1073-1078 [Abstract] [Full Text]  
• Chen, Y., Ruan, X. Z., Li, Q., Huang, A., Moorhead, J. F., Powis, S. H., Varghese, Z. (2007). Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells. Am. J. Physiol. Renal Physiol. 293: F680-F687 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Cavanaugh, K. L. (2007). Diabetes Management Issues for Patients With Chronic Kidney Disease. Clin. Diabetes 25: 90-97 [Abstract] [Full Text]  
• DeLoach, S. S., Mohler, E. R. III (2007). Peripheral Arterial Disease: A Guide for Nephrologists. CJASN 2: 839-846 [Abstract] [Full Text]  
• Nogueira, J., Weir, M. (2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN 2: 766-785 [Abstract] [Full Text]  
• Nanayakkara, P. W. B., van Guldener, C., ter Wee, P. M., Scheffer, P. G., van Ittersum, F. J., Twisk, J. W., Teerlink, T., van Dorp, W., Stehouwer, C. D. A. (2007). Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 167: 1262-1270 [Abstract] [Full Text]  
• Kim, Y.-L. (2007). CAN WE OVERCOME THE PREDESTINED POOR SURVIVAL OF DIABETIC PATIENTS? PERSPECTIVES FROM PRE- AND POST-DIALYSIS. pdi 27: S171-S175 [Abstract] [Full Text]